
Amber, a transpersonal psychotherapist, discusses the healing potential of non-ordinary states of consciousness.
Amber, a transpersonal psychotherapist, discusses the healing potential of non-ordinary states of consciousness.
August 4, 2021- This week’s Psychedelic Business News top stories…
Hello psychedelic investors! Today’s episode will be a little different. We will discuss the recent media coverage of psychedelic stocks and its role in psychedelic inspired companies’ future.
It appears that the mainstream media understands the potential for psychedelic stocks to disrupt the pharmaceutical Industry. Now understanding what this means, and its implications is extremely important for retail investors like you and me.
We’ll also zoom into one piece of media about MindMed (MMED/MMEDF) and Compass Pathways (CMPS), and explore how it hits the nail on the head.
We are going to do this because one, it’s a good article that I wanted to share with you
And two, it exemplifies my point that the mainstream understands the potential here, and might actually be on the right side of history.
P.S. I mention in the video that the article I’m discussing is by Yahoo Finance. It turns out the article is from OTC stock review.
For those interested in reading the entire article: https://ca.movies.yahoo.com/264-million-reasons-psychedelic-stocks-133000885.html
Time Stamps
0:00 – Intro
3:10 – Media Coverage on Tesla & Psychedelic Stocks
6:36 – Benefits of the media covering Psychedelic Companies like (MMEDF & CMPS)
8:05 – Influence on stock valuations and stealth investors
10:57 – 264 Million Reasons Why Psychedelic Stocks Have More Room To Grow
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MindmedStock #PsychedelicStocks
In this conversation, we discuss some critical points such as how he managed to heal himself through the use of Ayurveda and functional medicine which led him down the path to working with these interesting modalities, how ancestral healing has the ability to significantly influence an individual’s wellbeing overall, how his practice uses entheogens to cure physical ailments such as Traumatic Brain Injury, and more!
MAPS Phase 3 MDMA To Treat PTSD Trial Results Released [ GREAT NEWS For NUMI, MindMed, MYCO & Atai ]
Breaking NEWS: 67% of participants in a recent MAPS sponsored Phase III clinical trial focused on MDMA- assisted therapy no longer qualified for a diagnosis of PTSD, compared with 32% in the placebo group. Also, 88% of participants receiving psychedelic therapy experiences a clinically significant reduction in symptoms of PTSD.
Also, there were 0 cases of serious adverse side effects in the MDMA group.
So which companies will be the largest benefactors of these results?
Numinus Wellness (NUMI / LKYSF ): working in conjunction with MAPS in Canada to conduct a compassionate access trial to those with PTSD. The trial is either already recruiting patients, or is set to do so imminently
2.MindMed ( MMED / MNMD / MMQ) is also working with MDMA, and has recently completely a study on personalized dosing of MDMA. MindMed also has a Phase I trial looking at the effects of combining LSD with MDMA.
3. Atai life sciences is in the preclinical stages of using an MDMA derivative to treat PTSD, through their subsidiary EmpathBio.
4. Mydecine has a compound called MYCO-002, which is similar to MDMA, which they hope to start using in clinical trials soon.
5. Awakn Life Sciences, a private company, also will have a Phase II study looking at treating alcohol use disorder with MDMA.
Link to the article in question: https://www.nytimes.com/2021/05/03/health/mdma-approval.html?fbclid=IwAR3xMWgnKryfZnzWqB7mJ9GrkVuoQE79yC-kVEXJzOyF4n7JEcHOuobw7jQ#click=https://t.co/GVhm9i2wm3
Link to MindMed ( MMED / MNMD/ MMQ ) : https://mindmed.co/
Link to MYDECINE ( MYCO / MYCOF ): https://www.mydecine.com/
Link to Numinus (NUMI): https://numinus.ca/
Link to Atai Life Sceinces : https://www.atai.life/
Link to Awakn Life sciences: https://www.newsfilecorp.com/company/7226/Awakn-Life-Sciences-Inc.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
Clinical trials :
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #PsychedelicStocks #NUMIStock
Kelsey Ramsden, the President, and CEO of Mind Cure Health Inc. sheds light on the advancements Mind Cure is currently making.
Stephen Murphy, Co-Founder of Prohibition Partners, chats about the upcoming PSYCH Investor Summit taking place on April 21, 2021.
August 4, 2021- This week’s Psychedelic Business News top stories…
Hello psychedelic investors! Today’s episode will be a little different. We will discuss the recent media coverage of psychedelic stocks and its role in psychedelic inspired companies’ future.
It appears that the mainstream media understands the potential for psychedelic stocks to disrupt the pharmaceutical Industry. Now understanding what this means, and its implications is extremely important for retail investors like you and me.
We’ll also zoom into one piece of media about MindMed (MMED/MMEDF) and Compass Pathways (CMPS), and explore how it hits the nail on the head.
We are going to do this because one, it’s a good article that I wanted to share with you
And two, it exemplifies my point that the mainstream understands the potential here, and might actually be on the right side of history.
P.S. I mention in the video that the article I’m discussing is by Yahoo Finance. It turns out the article is from OTC stock review.
For those interested in reading the entire article: https://ca.movies.yahoo.com/264-million-reasons-psychedelic-stocks-133000885.html
Time Stamps
0:00 – Intro
3:10 – Media Coverage on Tesla & Psychedelic Stocks
6:36 – Benefits of the media covering Psychedelic Companies like (MMEDF & CMPS)
8:05 – Influence on stock valuations and stealth investors
10:57 – 264 Million Reasons Why Psychedelic Stocks Have More Room To Grow
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MindmedStock #PsychedelicStocks
In this conversation, we discuss some critical points such as how he managed to heal himself through the use of Ayurveda and functional medicine which led him down the path to working with these interesting modalities, how ancestral healing has the ability to significantly influence an individual’s wellbeing overall, how his practice uses entheogens to cure physical ailments such as Traumatic Brain Injury, and more!
MAPS Phase 3 MDMA To Treat PTSD Trial Results Released [ GREAT NEWS For NUMI, MindMed, MYCO & Atai ]
Breaking NEWS: 67% of participants in a recent MAPS sponsored Phase III clinical trial focused on MDMA- assisted therapy no longer qualified for a diagnosis of PTSD, compared with 32% in the placebo group. Also, 88% of participants receiving psychedelic therapy experiences a clinically significant reduction in symptoms of PTSD.
Also, there were 0 cases of serious adverse side effects in the MDMA group.
So which companies will be the largest benefactors of these results?
Numinus Wellness (NUMI / LKYSF ): working in conjunction with MAPS in Canada to conduct a compassionate access trial to those with PTSD. The trial is either already recruiting patients, or is set to do so imminently
2.MindMed ( MMED / MNMD / MMQ) is also working with MDMA, and has recently completely a study on personalized dosing of MDMA. MindMed also has a Phase I trial looking at the effects of combining LSD with MDMA.
3. Atai life sciences is in the preclinical stages of using an MDMA derivative to treat PTSD, through their subsidiary EmpathBio.
4. Mydecine has a compound called MYCO-002, which is similar to MDMA, which they hope to start using in clinical trials soon.
5. Awakn Life Sciences, a private company, also will have a Phase II study looking at treating alcohol use disorder with MDMA.
Link to the article in question: https://www.nytimes.com/2021/05/03/health/mdma-approval.html?fbclid=IwAR3xMWgnKryfZnzWqB7mJ9GrkVuoQE79yC-kVEXJzOyF4n7JEcHOuobw7jQ#click=https://t.co/GVhm9i2wm3
Link to MindMed ( MMED / MNMD/ MMQ ) : https://mindmed.co/
Link to MYDECINE ( MYCO / MYCOF ): https://www.mydecine.com/
Link to Numinus (NUMI): https://numinus.ca/
Link to Atai Life Sceinces : https://www.atai.life/
Link to Awakn Life sciences: https://www.newsfilecorp.com/company/7226/Awakn-Life-Sciences-Inc.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
Clinical trials :
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #PsychedelicStocks #NUMIStock
Kelsey Ramsden, the President, and CEO of Mind Cure Health Inc. sheds light on the advancements Mind Cure is currently making.
Stephen Murphy, Co-Founder of Prohibition Partners, chats about the upcoming PSYCH Investor Summit taking place on April 21, 2021.
August 4, 2021- This week’s Psychedelic Business News top stories…
Hello psychedelic investors! Today’s episode will be a little different. We will discuss the recent media coverage of psychedelic stocks and its role in psychedelic inspired companies’ future.
It appears that the mainstream media understands the potential for psychedelic stocks to disrupt the pharmaceutical Industry. Now understanding what this means, and its implications is extremely important for retail investors like you and me.
We’ll also zoom into one piece of media about MindMed (MMED/MMEDF) and Compass Pathways (CMPS), and explore how it hits the nail on the head.
We are going to do this because one, it’s a good article that I wanted to share with you
And two, it exemplifies my point that the mainstream understands the potential here, and might actually be on the right side of history.
P.S. I mention in the video that the article I’m discussing is by Yahoo Finance. It turns out the article is from OTC stock review.
For those interested in reading the entire article: https://ca.movies.yahoo.com/264-million-reasons-psychedelic-stocks-133000885.html
Time Stamps
0:00 – Intro
3:10 – Media Coverage on Tesla & Psychedelic Stocks
6:36 – Benefits of the media covering Psychedelic Companies like (MMEDF & CMPS)
8:05 – Influence on stock valuations and stealth investors
10:57 – 264 Million Reasons Why Psychedelic Stocks Have More Room To Grow
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MindmedStock #PsychedelicStocks
In this conversation, we discuss some critical points such as how he managed to heal himself through the use of Ayurveda and functional medicine which led him down the path to working with these interesting modalities, how ancestral healing has the ability to significantly influence an individual’s wellbeing overall, how his practice uses entheogens to cure physical ailments such as Traumatic Brain Injury, and more!
MAPS Phase 3 MDMA To Treat PTSD Trial Results Released [ GREAT NEWS For NUMI, MindMed, MYCO & Atai ]
Breaking NEWS: 67% of participants in a recent MAPS sponsored Phase III clinical trial focused on MDMA- assisted therapy no longer qualified for a diagnosis of PTSD, compared with 32% in the placebo group. Also, 88% of participants receiving psychedelic therapy experiences a clinically significant reduction in symptoms of PTSD.
Also, there were 0 cases of serious adverse side effects in the MDMA group.
So which companies will be the largest benefactors of these results?
Numinus Wellness (NUMI / LKYSF ): working in conjunction with MAPS in Canada to conduct a compassionate access trial to those with PTSD. The trial is either already recruiting patients, or is set to do so imminently
2.MindMed ( MMED / MNMD / MMQ) is also working with MDMA, and has recently completely a study on personalized dosing of MDMA. MindMed also has a Phase I trial looking at the effects of combining LSD with MDMA.
3. Atai life sciences is in the preclinical stages of using an MDMA derivative to treat PTSD, through their subsidiary EmpathBio.
4. Mydecine has a compound called MYCO-002, which is similar to MDMA, which they hope to start using in clinical trials soon.
5. Awakn Life Sciences, a private company, also will have a Phase II study looking at treating alcohol use disorder with MDMA.
Link to the article in question: https://www.nytimes.com/2021/05/03/health/mdma-approval.html?fbclid=IwAR3xMWgnKryfZnzWqB7mJ9GrkVuoQE79yC-kVEXJzOyF4n7JEcHOuobw7jQ#click=https://t.co/GVhm9i2wm3
Link to MindMed ( MMED / MNMD/ MMQ ) : https://mindmed.co/
Link to MYDECINE ( MYCO / MYCOF ): https://www.mydecine.com/
Link to Numinus (NUMI): https://numinus.ca/
Link to Atai Life Sceinces : https://www.atai.life/
Link to Awakn Life sciences: https://www.newsfilecorp.com/company/7226/Awakn-Life-Sciences-Inc.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
Clinical trials :
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #PsychedelicStocks #NUMIStock
Kelsey Ramsden, the President, and CEO of Mind Cure Health Inc. sheds light on the advancements Mind Cure is currently making.
Stephen Murphy, Co-Founder of Prohibition Partners, chats about the upcoming PSYCH Investor Summit taking place on April 21, 2021.
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.
Notifications